Affective and anxiety disorders: Prevalence, treatment and antidepressant medication use

Australian and New Zealand Journal of Psychiatry

Volumn 44, Issue 6, 2010, Pages 513-519

  Hollingworth, Samantha A ^a   Burgess, Philip M ^a   Whiteford, Harvey A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antidepressants; Anxiety; Depression; Prevalence; Treatment

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGE DISTRIBUTION; AGED; ANXIETY DISORDER; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DRUG APPROVAL; DRUG MARKETING; DRUG USE; DRUG UTILIZATION; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; OUTCOME ASSESSMENT; PRESCRIPTION; PREVALENCE; SELF REPORT; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; AUSTRALIA; CITALOPRAM; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; DRUG UTILIZATION; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SEX FACTORS; STATISTICAL DISTRIBUTIONS; YOUNG ADULT;

EID: 77952808368     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.3109/00048670903555138     Document Type: Article

References (40)

1. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The burden of disease and injury in Australia. Bull World Health Organ 2001; 79:1076-1084.
2. Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust 2008; 188:36-40.
3. Henderson S, Andrews G, Hall W. Australia's mental health: an overview of the general population survey. Aust N Z J Psychiatry 2000; 34:197-205.
4. Parslow RA, Jorm AF. Who uses mental health services in Australia? An analysis of data from the National Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry 2000; 34:997-1008.
5. Burgess PM, Pirkis JE, Slade TN, Johnston AK, Meadows GN, Gunn JM. Service use for mental health problems: findings from the 2007 National Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry 2009; 43:615-623.
6. Jorm AF, Christensen H, Griffiths KM. Changes in depression awareness and attitudes in Australia: the impact of beyondblue: the national depression initiative. Aust N Z J Psychiatry 2006; 40:42-46.
7. Hickie IB, Pirkis JE, Blashki GA, Groom GL, Davenport TA. General practitioners' response to depression and anxiety in the Australian community: a preliminary analysis. Med J Aust 2004; 181:S15-20.
8. Morley B, Pirkis J, Sanderson K et al. Better outcomes in mental health care: impact of different models of psychological service provision on patient outcomes. Aust N Z J Psychiatry 2007; 41:142-149.
9. Pirkis J, Stokes D, Morley B et al. Impacts of Australia's Better Outcomes in Mental Health Care Program for psychologists. Aust Psychologist 2006; 41:152-159.
10. Whiteford H, Doessel D, Sheridan JS. Uptake of Medical Benefits Schedule items by psychologists and other mental health practitioners. Clin Psychologist 2008; 12:50-56.
11. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5:e45.
12. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373:746-758.
13. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ 2003; 326:1008-11.
14. McManus P, Mant A, Mitchell PB, Montgomery WS, Marley J, Auland ME. Recent trends in the use of antidepressant drugs in Australia, 1990-1998. Med J Aust 2000; 173:458-461.
15. Smith AJ, Sketris I, Cooke C, Gardner D, Kisely S, Tett SE. A comparison of antidepressant use in Nova Scotia, Canada and Australia. Pharmacoepidemiol Drug Saf 2008; 17:697-706.
16. Department of Health and Ageing. Top 10 drugs. Aust Prescriber 2008; 31:164.
17. Kessler RC, Ustun TB. The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 2004; 13:93-121.
18. Slade T, Johnson A, Oakley-Browne M, Andrews G, Whiteford H. 2007 National Survey of Mental Health and Wellbeing: methods and key findings. Aust N Z J Psychiatry 2009; 43:594-605.
19. Hollingworth S, Siskind D. Anxiolytic, hypnotic and sedative medication use i Australia. Pharmacoepidemiol Drug Safety 2010; 19:280-288.
20. Australian Bureau of Statistics. Technical manual: National Survey of Mental Health and Wellbeing, confidentialised unit record files, Cat. No. 4329.0. Canberra: Australian Bureau of Statistics, 2007.
21. World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology. Oslo: Norwegian Institute of Public Health, 2008.
22. Australian Bureau of Statistics. Population by age and sex, Australian States and Territories, Cat. No. 3201.0. Canberra: Australian Bureau of Statistics, 2007.
23. Australian Government Department of Health and Ageing. Australian statistics on medicines 2006. Canberra: Department of Health and Ageing, 2008.
24. Jorm AF, Christensen H, Griffiths KM. The impact of beyond-blue: the national depression initiative on the Australian public's recognition of depression and beliefs about treatments. Aust N Z J Psychiatry 2005; 39:248-254.
25. Jorm AF, Christensen H, Griffiths KM. The public's ability to recognize mental disorders and their beliefs about treatment: changes in Australia over 8 years. Aust N Z J Psychiatry 2006; 40:36-41.
26. Cresswell KM, Fernando B, McKinstry B, Sheikh A. Adverse drug events in the elderly. Br Med Bull 2007; 83:259-274.
27. Friedman AL, Geoghegan SR, Sowers NM, Kulkarni S, Formica RN Jr. Medication errors in the outpatient setting: classification and root cause analysis. Arch Surg 2007; 142:278-283; discussion 284.
28. Mant A, Rendle VA, Hall WD et al. Making new choices about antidepressants in Australia: the long view 1975-2002. Med J Aust 2004; 181:S21-24.
29. McManus P, Mant A, Mitchell P, Britt H, Dudley J. Use of anti-depressants by general practitioners and psychiatrists in Australia. Aust N Z J Psychiatry 2003; 37:184-189.
30. Page AN, Swannell S, Martin G, Hollingworth S, Hickie IB, Hall WD. Sociodemographic correlates of antidepressant utilisation in Australia. Med J Aust 2009; 190:479-483.
31. Smith AJ, Sketris I, Cooke C, Gardner D, Kisely S, Tett SE. A comparison of benzodiazepine and related drug use in Nova Scotia and Australia. Can J Psychiatry 2008; 53:545-552.
32. Carlsten A, Waern M, Ekedahl A, Ranstam J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf 2001; 10:525-530.
33. Paulose-Ram R, Safran MA, Jonas BS, Gu Q, Orwig D. Trends in psychotropic medication use among U.S. adults. Pharmacoepide-miol Drug Saf 2007; 16:560-570.
34. Trifiro G, Barbui C, Spina E et al. Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003-2004. Pharmacoepidemiol Drug Saf 2007; 16:552-559.
35. Ufer M, Meyer SA, Junge O et al. Patterns and prevalence of antidepressant drug use in the German state of Baden-Wuerttemberg: a prescription-based analysis. Pharmacoepidemiol Drug Saf 2007; 16:1153-1160.
36. Craig D, Passmore AP, Fullerton KJ et al. Factors influencing prescription of CNS medications in different elderly populations. Pharmacoepidemiol Drug Saf 2003; 12:383-387.
37. Lawrenson RA, Tyrer F, Newson RB, Farmer RD. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 2000; 59:149-157.
38. Wei L, Chen R, MacDonald TM. Channelling of SSRIs and SNRIs use in the Tayside population, Scotland. Pharmacoepidemiol Drug Saf 2007; 16:859-866.
39. Munoz-Arroyo R, Sutton M, Morrison J. Exploring potential explanations for the increase in antidepressant prescribing in Scotland using secondary analyses of routine data. Br J Gen Pract 2006; 56:423-428.
40. Patten SB, Esposito E, Carter B. Reasons for antidepressant prescriptions in Canada. Pharmacoepidemiol Drug Saf 2007; 16:746-752.